Open an account

Certara

CERT · NASDAQ

$9.79+$0.335 (+3.54%)TodayMarket closed ·
Prev close $9.45

About CERT

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Employees
1,515
Headquarters
Radnor, Pennsylvania
Listed
Dec 11, 2020
Sector
Health Care
Industry
Health Care Technology
Website
certara.com

CERT key statistics

Market cap
1.44B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.81M
Volume
2.27M
Open price
$9.50
High today
$9.85
Low today
$9.37
52 Week high
$12.94
52 Week low
$4.45

Certara (CERT) at a glance

As of Oct 20, 2026, Certara (CERT) shares are priced at $9.79, giving the company a market cap of 1.44B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.37 and $9.85. The current price is 4.4% above the day's low and 0.7% below its high.

Volume so far is 2.27M shares, in line with the average of 2.81M shares a day.

Over the past year Certara has ranged from $4.45 to $12.94, and now sits 63% of the way up that range.

Certara met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.08 per share against an estimate of $0.0953.

The average analyst price target is $8.66, 11.5% below the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

45%of 11 analyst ratings say Buy
  • Buy45.5%
  • Hold54.5%
  • Sell0.0%
Price target · 13 analystsAvg $8.66
Low
$7.07
Now
$9.79
High
$10.50

CERT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 20.3% on average.

  1. Q3 FY24: reported $0.13 per share against an estimate of $0.1122
  2. Q4 FY24: reported $0.15 per share against an estimate of $0.1295
  3. Q1 FY25: reported $0.14 per share against an estimate of $0.1131
  4. Q2 FY25: reported $0.07 per share against an estimate of $0.1048
  5. Q3 FY25: reported $0.14 per share against an estimate of $0.1113
  6. Q4 FY25: reported $0.09 per share against an estimate of $0.1141
  7. Q1 FY26: reported $0.09 per share against an estimate of $0.1089
  8. Q2 FY26: reported $0.08 per share against an estimate of $0.0953

CERT news

  • Press releaseGlobe Newswire

    The Market Just Told You Which Layer Of AI Biology It Is Paying For

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • Press releasePRNewswire

    An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • Lekha Gupta

    Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & More

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT

Similar companies

Companies in the same industry as Certara

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.